Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotech company with a market capitalization of approximately $748 million, announced Monday that Douglas Barry, its Chief Legal and Compliance Officer and Corporate Secretary, has notified the board of directors of his intention to resign from his positions, effective September 12, 2025. According to a statement based on a recent SEC filing, Barry is leaving the company to pursue another opportunity. The news comes as TNGX shares have shown remarkable momentum, posting a 200% return over the past six months.
The company, headquartered in Boston, Massachusetts, disclosed that Barry’s resignation was communicated to the board on August 21, 2025. No additional details regarding his future plans or a successor were provided in the filing.
Tango Therapeutics’ common stock is listed on the Nasdaq Global Market under the symbol TNGX.
This information is based on a press release statement filed with the Securities and Exchange Commission.
In other recent news, Tango Therapeutics has made significant strides in its clinical trials and received notable analyst attention. The company announced it has dosed the first patient in a Phase 1/2 trial for its TNG462 drug, which is being tested in combination with Revolution Medicines’ RAS inhibitors. This trial targets patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer, addressing a substantial need given that nearly all MTAP-deleted pancreatic cancers and about 30% of lung cancers have a RAS mutation.
Analysts have responded positively to these developments. Piper Sandler initiated coverage on Tango Therapeutics with an Overweight rating, citing growing investor confidence in the synthetic lethality space and potential for Tango’s PRMT5-inhibitor. They set a price target of $11.00. Additionally, H.C. Wainwright reiterated its Buy rating with a $13.00 price target, following the announcement of the trial’s commencement. These ratings reflect optimism about Tango Therapeutics’ ongoing research and development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.